A Simple Key For ABBV-744 BRD4 inhibition in cancer cell lines Unveiled
In Phase C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, members will receive ABBV-744 and ruxolitinib. Individuals will acquire treatment until finally illness progression or maybe the participants are not able to tolerate the study drugs.- "Our study discovered the essential function from the KLF16/MYC regulatory axis in m